Menarini, NewAmsterdam Pharma win EU approval for cholesterol drugs
The European Commission has granted marketing authorization for Menarini Group and NewAmsterdam Pharma's Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia. This marks the first regulatory approval of obice